Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232143 | 0.93 | PNMT (0.56) | PNMTCYP2A6TAAR1LOXL2CA12 | |
| SCHEMBL29463734 | 0.86 | CYP2A6 (0.52) | PNMTCYP2A6TAAR1LOXL2CA12 | |
| SCHEMBL17907448 | 0.86 | CYP2A6 (0.52) | PNMTCYP2A6TAAR1LOXL2CA12 | |
| SCHEMBL17232441 | 0.78 | CYP2A6 (0.59) | CYP2A6 | |
| SCHEMBL15351870 | 0.78 | CYP2A6 (0.48) | CYP2A6MAOB | |
| SCHEMBL9016348 | 0.78 | ASIC3 (0.57) | PNMTCYP2A6TAAR1LOXL2CA12 | |
| SCHEMBL30027002 | 0.78 | CYP2A6 (0.72) | CYP2A6MAOB | |
| SCHEMBL2473615 | 0.78 | CYP2A6 (0.72) | CYP2A6MAOB | |
| SCHEMBL25220014 | 0.76 | LOXL2 (0.54) | CYP2A6LOXL2CA12CA1CA2 | |
| SCHEMBL31590838 | 0.76 | LOXL2 (0.54) | CYP2A6LOXL2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2657214-B1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL CO (JP) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-8993774-B2 | Process for production of aromatic alcohol or heterocyclic aromatic alcohol | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-11-14 | — | — | US | disclosed |
| EP-2657214-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | Mitsubishi Gas Chemical Company, Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-1615890-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2004089903-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | PNMT 2513/4885CYP2A6 253/4885TAAR1 2647/4885 |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | PNMT 812/4885CYP2A6 4004/4885TAAR1 2213/4885 |
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | ADH1C, ADH1A, ADH5 | PNMT 334/4885CYP2A6 278/4885TAAR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.